Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8N9I0
UPID:
SYT2_HUMAN
Alternative names:
Synaptotagmin II
Alternative UPACC:
Q8N9I0; Q496K5; Q8NBE5
Background:
Synaptotagmin-2, also known as Synaptotagmin II, plays a crucial role in the synaptic vesicle trafficking at active zones of synapses, exhibiting calcium-dependent phospholipid and inositol polyphosphate binding properties. It is also involved in dendrite formation by melanocytes, highlighting its significance in neural and skin cell functions.
Therapeutic significance:
Synaptotagmin-2 is implicated in congenital myasthenic syndromes (CMS), specifically CMS7A and CMS7B, which are characterized by neuromuscular transmission failures. Understanding the role of Synaptotagmin-2 in these conditions could pave the way for developing targeted therapies, offering hope for patients suffering from these debilitating disorders.